Filing Details
- Accession Number:
- 0001209191-16-100441
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-02-19 15:50:01
- Reporting Period:
- 2016-02-17
- Filing Date:
- 2016-02-19
- Accepted Time:
- 2016-02-19 15:50:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1245104 | Globeimmune Inc | GBIM | Pharmaceutical Preparations (2834) | 841353925 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1013469 | W John Littlechild | C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141 | No | No | No | Yes | |
| 1013473 | H James Cavanaugh | C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141 | No | No | No | Yes | |
| 1013603 | R Harold Werner | C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141 | No | No | No | Yes | |
| 1202615 | Healthcare Ventures Vii Lp | 47 Thorndike Street Suite B1-1 Cambridge MA 02141 | No | No | No | Yes | |
| 1262326 | Christopher Mirabelli | C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141 | No | No | No | Yes | |
| 1262327 | Augustine Lawlor | C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141 | Yes | No | No | Yes | |
| 1330957 | Healthcare Partners Vii, L.p. | 47 Thorndike Street Suite B1-1 Cambridge MA 02141 | No | No | No | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2016-02-17 | 5,000 | $1.53 | 564,267 | No | 4 | S | Indirect | By Partnership |
| Common Stock | Disposition | 2016-02-18 | 5,000 | $1.40 | 559,267 | No | 4 | S | Indirect | By Partnership |
| Common Stock | Disposition | 2016-02-19 | 5,000 | $1.39 | 554,267 | No | 4 | S | Indirect | By Partnership |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By Partnership |
| No | 4 | S | Indirect | By Partnership |
| No | 4 | S | Indirect | By Partnership |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.48 - $1.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote (1) to this Form 4.
- These securities are held of record by HealthCare Ventures VII, L.P. ("HCVVII"). HealthCare Partners VII, L.P. ("HCPVII") is the General Partner of HCVVII. Each of James Cavanaugh, Christopher Mirabelli, Harold Werner, John Littlechild and Augustine Lawlor are general partners of HCPVII and exercise shared voting and investment power with respect to the shares owned by HCVVII. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of their proportionate pecuniary interest therein. In addition, Mr. Lawlor is a member of the Board of Directors of the Issuer.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.40 - $1.44, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote (3) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.35 - $1.42, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote (4) to this Form 4.
Billionaire Hedge Funds
